Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Eugene R. Ahn; Pam K. Mangat; Elizabeth Garrett-Mayer; Susan Halabi; Elie G. Dib; Daniel E. Haggstrom; Kathryn B. Alguire; Carmen J. Calfa; Timothy L. Cannon; Pamela A. Crilley; Anu G. Gaba; Alissa S. Marr; Ashish Sangal; Ramya Thota; Kaitlyn R. Antonelli; Samiha Islam; Andrew L. Rygiel; Suanna S. Bruinooge; Richard L. Schilsky

Journal Article

Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Ahn E
Mangat P
Garrett-Mayer E
et al.

JCO Precision Oncology (2020) (4) 757-766

DOI: 10.1200/po.20.00037

N/ACitations

47Readers

Get full text

Abstract

PURPOSEThe Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially availab...

Cite

CITATION STYLE

APA

Ahn, E. R., Mangat, P. K., Garrett-Mayer, E., Halabi, S., Dib, E. G., Haggstrom, D. E., … Schilsky, R. L. (2020). Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, (4), 757–766. https://doi.org/10.1200/po.20.00037

Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Abstract

Cite

Register to see more suggestions